Recurrent squamous cell carcinoma of the skin treated with immunotherapy

J Cancer Res Ther. 2022 Dec;18(Supplement):S495-S497. doi: 10.4103/jcrt.JCRT_1018_20.

Abstract

Squamous cell carcinoma (SCC) has a good prognosis, while metastatic tumors have aggressive behavior. Immunotherapy has become a standard line of treatment in metastatic cancers; pembrolizumab has shown promising results and improved quality of life in recurrent and metastatic cancers. We report a case of recurrent SCC of the skin with extensive disease and a known case of human immunodeficiency virus. He completed standard lines of treatment and currently on immunotherapy. After 3 cycles of immunotherapy plus chemotherapy, he got a complete metabolic response. Our experience showed palliative benefits and increased quality of life.

Keywords: Immunosuppression; immunotherapy; pembrolizumab; squamous cell carcinoma.

Publication types

  • Case Reports

MeSH terms

  • Carcinoma, Squamous Cell* / pathology
  • Humans
  • Immunotherapy / methods
  • Male
  • Neoplasm Recurrence, Local / drug therapy
  • Quality of Life*
  • Remission Induction